Pipeline
Our pipeline
Our TCR-based therapies hold the potential to transform the lives of people living with cancer, including many types of solid tumors, and a wide spectrum of immune-mediated diseases. We are advancing a robust and differentiated pipeline of specificity- and affinity-enhanced soluble TCR (specTR) therapeutics for accelerated clinical impact, with an initial focus on solid tumour indications with high unmet medical need.
Our lead assets
ENGI-002
ENGI-002 specTR is a T-cell engager that targets MAGE-A3 and offers therapeutic potential against multiple solid tumours. MAGE-A3 is expressed in many solid tumours, including melanoma, bladder cancer, gastric cancer, and non-small cell lung cancer (NSCLC), and exhibits low expression on normal tissues. This clinically validated target has few programs currently in development, and previous attempts to target MAGE-A3 have been hindered due to unexpected cross-reactivity.
Development of ENGI-002 is focused on effective targeting of MAGE-A3 while avoiding safety concerns stemming from cross-reactivity. ENGI-002 has demonstrated selective, subnanomolar affinity to MAGE-A3 in preclinical studies and is expected to enter clinical studies in 2025.
ENGI-003
ENGI-003 is a natural killer (NK) cell-engaging specTR that targets a protein expressed in over 70% of hepatocellular carcinoma (HCC) tumours. Current treatments for HCC have limited efficiency and durability of responses, leaving up to half of patients with few alternative treatment options.
Recognizing that NK cell numbers and activity are correlated with a better response, ENGI-003 is focused on providing a safe, effective alternative to existing therapies by leveraging specTR technology to redirect NK cell activity against HCC and is expected to enter clinical studies in 2026.